Metastatic Castration-Sensitive Prostate Cancer, If Treatment Intensification Is the Standard, Who and How Can We Treatment Deintensify?
Metastatic castration-sensitive prostate cancer (mCSPC) is a disease state where the benefits of treatment intensification are clear. Androgen receptor pathway inhibitors (ARPIs) offer overall survival benefit when added to conventional androgen deprivation therapy (ADT). The specific ARPIs include abiraterone acetate,1,2 enzalutamide,3,4 and apalutamide.5 Docetaxel chemotherapy offers survival benefit for patients with high volume disease,6 and either abiraterone7 or darolutamide8 offer survival benefit when added to ADT and docetaxel for patients, especially for those with de novo and high-volume mCSPC.
Evan Y. Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder, and testicular cancer and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biological mechanisms of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Section Head, Cancer Medicine, Clinical Research Division Fred Hutchinson Cancer Center
- Medical Director, Clinical Research Support Fred Hutchinson Cancer Research Consortium
- Professor of Medicine Division of Oncology, Department of Medicine University of Washington School of Medicine Seattle, WA
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.